ZLN024

ZLN024

CAT N°: 21644
Price:

From 145.00 123.25

ZLN024 is an allosteric activator of AMP-activated protein kinase (AMPK) heterotrimers (EC50s = 0.42 and 0.95 µM for ?1?1?1 and ?2?1?1, respectively).{33850} Activation of AMPK by ZLN024 requires phosphorylation of AMPK on Thr172, and ZLN024 protects Thr172 from dephosphorylation by protein phosphatase 2C?.{33850} ZLN024 stimulates glucose uptake and fatty acid oxidation in L6 myotubes. In primary hepatocytes, ZLN024 decreases fatty acid synthesis and glucose output.{33850} ZLN024 reduces liver triacylglycerol and total cholesterol content and improves glucose tolerance in db/db mice.{33850}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[2-(2-bromo-4-methylphenoxy)ethyl]thio]-pyrimidine
  • Correlated keywords
    • 1883548-91-1 ZLN-024 24 a1b1g1 a2b1g1 a1 b1 g1 a2 2Ca PP-2Ca PP2Ca PP2C? thr-172 threonine L-6
  • Product Overview:
    ZLN024 is an allosteric activator of AMP-activated protein kinase (AMPK) heterotrimers (EC50s = 0.42 and 0.95 µM for ?1?1?1 and ?2?1?1, respectively).{33850} Activation of AMPK by ZLN024 requires phosphorylation of AMPK on Thr172, and ZLN024 protects Thr172 from dephosphorylation by protein phosphatase 2C?.{33850} ZLN024 stimulates glucose uptake and fatty acid oxidation in L6 myotubes. In primary hepatocytes, ZLN024 decreases fatty acid synthesis and glucose output.{33850} ZLN024 reduces liver triacylglycerol and total cholesterol content and improves glucose tolerance in db/db mice.{33850}

We also advise you